Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones
un post del usano CAUTION1ST en relacion a la persona en Jaffrays que ha suscrito el upgrade de hoy. Del tal CAUTION1ST ya he colgado en varias ocasiones post suyos. Sabe un huevo de THLD.
"Dr. Charles Duncan is managing director and senior research analyst in Piper's biotechnology research platform. He will isbased in the firm’s New York office, focused specifically on small- and mid-cap emerging growth biotechnology companies.
Duncan has more than 17 years of sell-side experience, most recently serving as an analyst at JMP Securities since 2002, and previously at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis.
... myfriends at CALPERS and Sanford Bernstein like his work a lot. They point out his ability to see big picture. They like his conservative approach and thorough research that extends beyond the immediate term noise, i.e. his low price target when he picked up Threshold but his doubling of that PT after one on one talks with the company. He is the only analyst I recall that has really mentioned the broad application possibilities of TH-302 instead of looking at just one cancer treatment at a time."
